Improved hepatitis C treatment response in younger patients: findings from the UK HCV National Register cohort study

SUMMARYIn a cohort of 272 treatment-naive individuals with chronic hepatitis C infection acquired on a known date who were enrolled in the UK HCV National Register, a progressive improvement in response to treatment was found with the evolution of antiviral therapies from 20% (25/122) for interferon monotherapy to 63% (55/88) for pegylated interferon+ribavirin therapy. Multivariable analysis results showed increasing age to be associated with poorer response to therapy [odds ratio (OR) 0·84, 95% confidence interval (CI) 0·72–0·99, P=0·03] whereas time since infection was not associated with response (OR 0·93, 95% CI 0·44–1·98, P=0·85). Other factors significantly associated with a positive response were non-type 1 genotype (P<0·0001) and combination therapies (P<0·0001). During the first two decades of chronic HCV infection, treatment at a younger age was found to be more influential in achieving a sustained viral response than treating earlier in the course of infection.

Download Full-text

The HCV National Register: towards informing the natural history of hepatitis C infection in the UK

Journal of Viral Hepatitis ◽

10.1046/j.1365-2893.2000.00255.x ◽

2000 ◽

Vol 7 (6) ◽

pp. 420-427 ◽

Cited By ~ 14

Author(s):

H. E. Harris ◽

M. E. Ramsay ◽

J. Heptonstall ◽

K. Soldan ◽

K. P. Eldridge ◽

...

Keyword(s):

Hepatitis C ◽

Natural History ◽

Hepatitis C Infection ◽

National Register ◽

History Of ◽

The Uk

Download Full-text

Response factors to pegylated interferon-alfa/ribavirin treatment in chronic hepatitis C patients genotype 1b

Archives of Biological Sciences ◽

10.2298/abs1401193j ◽

2014 ◽

Vol 66 (1) ◽

pp. 193-201 ◽

Cited By ~ 1

Author(s):

Snezana Jovanovic-Cupic ◽

S. Glisic ◽

M. Stanojevic ◽

N. Vasiljevic ◽

T. Bojic-Milinovic ◽

...

Keyword(s):

Chronic Hepatitis ◽

Viral Load ◽

Hepatitis C ◽

Combination Therapy ◽

Chronic Hepatitis C ◽

Sustained Viral Response ◽

Therapy Response ◽

Pegylated Interferon ◽

Response To Therapy ◽

Genotype 1B

Hepatitis C virus infection is the most common chronic blood-borne infection and one of the most important causes of chronic liver disease. Knowing the predictors associated with pegylated interferon/ribavirin (PEG-IFN/RBV) combination therapy response is important for evidence-based treatment recommendations. The goal of this study was to identify host and viral factors of response to PEG-IFN/RBV treatment in chronic hepatitis C genotype 1b patients. We have examined the relationship between gender, age, level of alanine aminotransferase (ALT), viral load and liver fibrosis progression on therapy response. ALT level and viral load were evaluated before starting treatment with combination therapy. The elevated levels of ALT and route of HCV transmission were found to be significantly associated with the response to therapy in HCV-infected patients. Our findings may be useful for estimating a patient?s likelihood of achieving sustained viral response.

Download Full-text

EFFICACY OF SOFOSBUVIR AND DACLATASVIR IN COMPENSATED CHRONIC HEPATITIS C INFECTION: A SINGLE CENTER, OPEN-LABEL AND PROOF OF CONCEPT STUDY

10.36106/5009819 ◽

2021 ◽

pp. 27-30

Author(s):

Manisha Thakur ◽

Anurag Chauhan ◽

Prashant Jambunathan ◽

Shikha Awasthi ◽

Thilagavathi K ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Sustained Virological Response ◽

Chronic Hepatitis C ◽

Virological Response ◽

Sustained Viral Response ◽

Hcv Rna ◽

Hepatitis C Infection ◽

Genotype 3 ◽

Treatment Naïve

AIMS AND OBJECTIVES: The advent of directly acting agents for the treatment of Hepatitis C infection has forever transformed our understanding and management of viral infections. With over 95 % patients achieving a sustained viral response at 12 weeks with some of these newly inducted agents, the prospect of eradicating the Hepatitis C virus seems like an achievable target, which makes this one of the most important discoveries in modern medicine. We studied the combination of Sofosbuvir and Daclatasvir in patients with chronic hepatitis C infection (Genotype 3) to assess the rates of sustained virological response at 12 weeks. We studied 67 treatment naive METHODS: patients with compensated chronic hepatitis C infection (genotype 3). They were all started on Tab Sofosbuvir 400 mg daily and Tab Daclatasvir 60 mg once daily for 12 weeks and followed up for a total of 24 weeks, which includes a treatment duration and observation period of 12 weeks each. The patients were monitored with HCV RNA levels at one, three and six months, with as many evaluations of liver function and routine hemogram. Our results show that 70.5% (p<0.05) achieved a rapid vi RESULTS: rological response, 88.5% (p<0.05) achieved an end of treatment response and, similarly, an impressive 88.05% (p<0.05) showed a sustained virological response at the end of 12 weeks. One patient who developed a psoriasiform rash discontinued the medication and was excluded from the analysis, as duration of treatment had not been completed. No major dose related adverse events were reported. Sofosbuvir and Daclatasvir is an acceptable, well tolerated regimen for treatment naive, CONCLUSIONS: compensated patients with genotype 3 infection. Based on our observations and data, we recommend this as the rst line DAA for patient with compensated genotype 3 infection until medications with higher SVR 12 are available in the Indian market.

Download Full-text

Estimating hepatitis C infection acquired in England, 1986–2000

Epidemiology and Infection ◽

10.1017/s0950268809002143 ◽

2009 ◽

Vol 137 (9) ◽

pp. 1249-1254 ◽

Cited By ~ 8

Author(s):

M. A. BALOGUN ◽

A. J. VYSE ◽

L. M. HESKETH ◽

G. KAFATOS ◽

J. V. PARRY ◽

...

Keyword(s):

Hepatitis C ◽

General Population ◽

Multivariable Analysis ◽

Population Level ◽

Hepatitis C Infection ◽

Cross Sectional ◽

Health Region ◽

Hcv Prevalence ◽

Significant Difference ◽

The Uk

SUMMARYHepatitis C is a global health problem and in the UK seroprevalence studies have mainly concentrated on specific high-risk groups. The aim of this study was to determine changes in the prevalence of antibody to hepatitis C virus in England using residual specimens collected between 1986 and 2000 reflecting the general population. A cross-sectional study design using a convenience collection of serum specimens from adult patients submitted to laboratories in the years 1986, 1991, 1996 and 2000 from a total of 19 laboratories around England were investigated. The main outcome was to determine anti-HCV prevalence and the average incidence occurring between 1986 and 2000 and factors associated with infection. Multivariable analysis of results from all years showed there was a significant difference in prevalence between males and females (P<0·001), birth cohort (P<0·001) and by health region (P<0·001). An average of 0·72% (95% CI 0–1·65%) of those susceptible to HCV born between 1950 and 1970 were estimated to have acquired the infection between 1986 and 2000. Analysis of this convenience serum collection suggests that HCV prevalence is low in the general population, and is associated with period of birth, gender and health region. There was evidence to support a low incidence of HCV infection in those born between 1950 and 1970 over the period 1986–2000 which, at the population level, equated to a substantial burden of infection (~106 000 persons). Continued surveillance and prevention targeted at injecting drug users are essential for the control of hepatitis C in the UK.

Download Full-text

Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1

Journal of Gastrointestinal and Liver Diseases ◽

10.15403/jgld.2014.1121.251.a2a ◽

2016 ◽

Vol 25 (1) ◽

pp. 15-24 ◽

Cited By ~ 2

Author(s):

Tim Zimmermann ◽

Dietrich Hueppe ◽

Stefan Mauss ◽

Peter Buggisch ◽

Heike Pfeiffer-Vornkahl ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Antiviral Therapy ◽

Interferon Alpha ◽

Virological Response ◽

Sustained Viral Response ◽

Pegylated Interferon ◽

Genotype 1 ◽

Pegylated Interferon Alpha ◽

Viral Response

Background & Aims: Smoking has multiple effects on factors influencing hepatitis C and antiviral therapy, including lipid metabolism, fibrosis, platelet count and adherence aspects. The aim of this analysis was to determine the impact of smoking on hepatitis C virus antiviral therapy. Methods: Data of two cohorts of an observational multicenter study including therapy-naïve patients infected with genotype 1 hepatitis C virus (HCV) treated with dual antiviral therapy (n=7,796) with pegylated interferon alpha 2a in combination with ribavirin, or triple antiviral therapy (n=1,122) containing telaprevir or boceprevir, were analysed. Results: In the univariate matched pair analysis of dual antiviral therapy patients (n=584), smoking was significantly associated with lower sustained viral response rates (p=0.026, OR 0.69 CI: 0.50 – 0.96). The effect of smoking on sustained viral response remained significant (p=0.028, OR 0.67 CI: 0.47 – 0.96) in the multivariate analysis when adjusting for all other baseline parameters with a significant association in the univariate analysis, i.e. diabetes, fibrosis, body mass index, transaminases and baseline viral load. Under protease inhibitors the influence of smoking on virological response did not arise. Conclusions: Smoking has a negative impact on antiviral therapy in naïve patients infected with HCV genotype 1 independently of age, gender, history of drug use or alcoholic liver disease. The effects of smoking might be overcome by the new antiviral agents.Abbreviations: APRI: AST to platelet ratio index; DAA: direct antiviral agent; DT: dual antiviral therapy; EoTR: end of treatment response; RVR: rapid virological response; EVR: early virological response; HCV: hepatitis C virus; IFN: interferon alpha; MPA: Matched Pair Analysis; NS: non-smokers; PEG-IFN: pegylated interferon alpha 2a; PI: protease inhibitor; RBV: ribavirin; SAE: serious adverse event; SOC: standard of care; S: smokers; SVR: sustained viral response.

Download Full-text